Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Fv-IgG) (BSDG-041)

Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD19 IgG with similar domains from an anti-CD3 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet

Specifications

Targets

CD19 & CD3

Type

Appended IgGs

Species Reactivity

Human

Target 1

CD19

Host Animal 1

Mouse

Target 2

CD3

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Email: